RE: 52p target broker note22 Oct 2024 14:32
Here is what Trinity Delta actually said on 18th October...
Oxford BioDynamics is leading the way in 3D genomic diagnostics, developing innovative and clinically robust tests using its proprietary EpiSwitch platform. EpiSwitch CiRT (Checkpoint Inhibitor Response Test), predicts a patient’s response to cancer immunotherapy, and the PROWES registry study is underway to generate uptake and to support inclusion in key guidelines. EpiSwitch PSE, for prostate cancer, has recently been launched and is initially targeting the concierge medicine sector in the US. Growing testing volumes will require ongoing commercial investment. Our DCF-based valuation of £162m ($203m), or 52p/share assumes OBD can successfully navigate the Q125 cash shortfall, and deliver on the sales potential of these tests.